Key result
The 2013 updated PH classification maintains the prior scheme but removes PPHN from Group 1.
Why the study?
The clinical classification of pulmonary hypertension required updates to reflect new understanding and to create a comprehensive classification for both adults and children.
Answers are grounded in this paper and cite their sources.
Consensus review demonstrates updated categorization criteria for pulmonary hypertension in affected cohorts, highlighting refined diagnostic boundaries for tailored therapeutic management.
In 1998, a clinical classification of pulmonary hypertension (PH) was established, categorizing PH into groups which share similar pathological and hemodynamic characteristics and therapeutic approaches. During the 5th World Symposium held in Nice, France, in 2013, the consensus was reached to maintain the general scheme of previous clinical classifications. However, modifications and updates especially for Group 1 patients (pulmonary arterial hypertension [PAH]) were proposed. The main change was to withdraw persistent pulmonary hypertension of the newborn (PPHN) from Group 1 because this entity carries more differences than similarities with other PAH subgroups. In the current classification, PPHN is now designated number 1. Pulmonary hypertension associated with chronic hemolytic anemia has been moved from Group 1 PAH to Group 5, unclear/multifactorial mechanism. In addition, it was decided to add specific items related to pediatric pulmonary hypertension in order to create a comprehensive, common classification for both adults and children. Therefore, congenital or acquired left-heart inflow/outflow obstructive lesions and congenital cardiomyopathies have been added to Group 2, and segmental pulmonary hypertension has been added to Group 5. Last, there were no changes for Groups 2, 3, and 4.
No takes yet. Share an insight, caveat, or question.
Simonneau et al. (2013) conducted a review in Pulmonary hypertension. The 2013 updated clinical classification of pulmonary hypertension maintained the previous general scheme while withdrawing persistent pulmonary hypertension of the newborn from Group 1.
Synapse has enriched 10 related papers. Consider them for comparative context: